NCT00556673View on ClinicalTrials.gov

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Asthma
Interventions
DRUG

indacaterol maleate/mometasone furoate

Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.

DRUG

placebo to indacaterol maleate/mometasone furoate

Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.

DRUG

fluticasone proprionate / salmeterol xinafoate

Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.

Trial Locations (2)

14050

Novartis Investigator Site, Berlin

86000

Novartis Investigator Site, Poitiers

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Novartis

INDUSTRY

NCT00556673 - Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma | Biotech Hunter | Biotech Hunter